Table 2: Randomized, double-blinded, parallel-group, placebo-controlled comparative studies of bilastine with other antihistamines: study characteristics and results of primary efficacy outcome measures.

StudyIndicationPrimary outcomeArm 1; Arm 2; Arm 3; Results for primary outcome

[14]Seasonal allergic rhinitisAUC for TSS from baseline 14 daysBilastine 20 mg; 233Desloratadine 5 mg; 242 Placebo; 245Bilastine significantly better than placebo
Bilastine versus desloratadine: NS

[15]Seasonal allergic rhinitisAUC for TSS from baseline 14 daysBilastine 20 mg; 227Cetirizine 10 mg; 228Placebo; 226 Bilastine significantly better than placebo
Bilastine versus cetirizine: NS

[16]Perennial allergic rhinitisAUC for TSS from baseline 28 daysBilastine 20 mg; 214Cetirizine 10 mg; 217Placebo; 219 Bilastine versus cetirizine and placebo: NS

[17]
Chronic idiopathic urticariaChange in TSS from baseline 28 daysBilastine 20 mg; 173Levocetirizine 5 mg; 165Placebo; 184Bilastine significantly better than placebo
Bilastine versus levocetirizine: NS

AUC: area under curve; TSS: total symptom score; NS: not statistically significantly better.